Characteristics of 1061 study patients and CB grafts
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Male | 588 (55) |
| Female | 473 (45) |
| Age, y | |
| 0-1 | 137 (13) |
| 2-9 | 426 (40) |
| 10-19 | 261 (25) |
| 20-39 | 147 (14) |
| 40 or more | 90 (8) |
| Ancestry* | |
| Asian | 41 (4) |
| African | 180 (17) |
| Hispanic | 218 (21) |
| Native American | 8 (1) |
| Middle Eastern | 29 (3) |
| White | 555 (54) |
| Other | 3 (< 1) |
| Diagnosis | |
| ALL | 463 (44) |
| AML | 350 (33) |
| CML | 126 (12) |
| JCML | 31 (3) |
| Other leukemia | 20 (2) |
| Myelodysplasia | 71 (7) |
| Disease risk† | |
| Early-stage disease | 240 (27) |
| Intermediate-stage disease | 403 (46) |
| Advanced-stage disease | 242 (27) |
| Conditioning | |
| TBI-based | 672 (63) |
| Chemotherapy only | 300 (28) |
| Unknown | 89 (8) |
| Immunosuppression | |
| CSA/corticosteroids | 530 (50) |
| Methotrexate-based | 166 (16) |
| Other | 139 (13) |
| Unknown | 226 (21) |
| Year of transplant | |
| 1993-1996 | 192 (18) |
| 1997-1999 | 384 (36) |
| 2000-2002 | 213 (20) |
| 2003-2006 | 272 (26) |
| Center | |
| US center, > 50 NYBC CBT | 330 (31) |
| US center, < 50 NYBC CBT | 461 (43) |
| Non-US center | 270 (25) |
| HLA match | |
| 0 mismatch | 56 (5) |
| 1 mismatch | 352 (33) |
| 2 mismatch | 588 (55) |
| 3 mismatch | 65 (6) |
| Cryopreserved TNC (geometric mean) | |
| 0.7-2.4 × 107 TNC/kg (1.8) | 239 (23) |
| 2.5-4.9 × 107 TNC/kg (3.5) | 408 (38) |
| 5.0-9.9 × 107 TNC/kg (6.9) | 280 (26) |
| More than 10.0 × 107 TNC/kg (13.6) | 134 (13) |
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Male | 588 (55) |
| Female | 473 (45) |
| Age, y | |
| 0-1 | 137 (13) |
| 2-9 | 426 (40) |
| 10-19 | 261 (25) |
| 20-39 | 147 (14) |
| 40 or more | 90 (8) |
| Ancestry* | |
| Asian | 41 (4) |
| African | 180 (17) |
| Hispanic | 218 (21) |
| Native American | 8 (1) |
| Middle Eastern | 29 (3) |
| White | 555 (54) |
| Other | 3 (< 1) |
| Diagnosis | |
| ALL | 463 (44) |
| AML | 350 (33) |
| CML | 126 (12) |
| JCML | 31 (3) |
| Other leukemia | 20 (2) |
| Myelodysplasia | 71 (7) |
| Disease risk† | |
| Early-stage disease | 240 (27) |
| Intermediate-stage disease | 403 (46) |
| Advanced-stage disease | 242 (27) |
| Conditioning | |
| TBI-based | 672 (63) |
| Chemotherapy only | 300 (28) |
| Unknown | 89 (8) |
| Immunosuppression | |
| CSA/corticosteroids | 530 (50) |
| Methotrexate-based | 166 (16) |
| Other | 139 (13) |
| Unknown | 226 (21) |
| Year of transplant | |
| 1993-1996 | 192 (18) |
| 1997-1999 | 384 (36) |
| 2000-2002 | 213 (20) |
| 2003-2006 | 272 (26) |
| Center | |
| US center, > 50 NYBC CBT | 330 (31) |
| US center, < 50 NYBC CBT | 461 (43) |
| Non-US center | 270 (25) |
| HLA match | |
| 0 mismatch | 56 (5) |
| 1 mismatch | 352 (33) |
| 2 mismatch | 588 (55) |
| 3 mismatch | 65 (6) |
| Cryopreserved TNC (geometric mean) | |
| 0.7-2.4 × 107 TNC/kg (1.8) | 239 (23) |
| 2.5-4.9 × 107 TNC/kg (3.5) | 408 (38) |
| 5.0-9.9 × 107 TNC/kg (6.9) | 280 (26) |
| More than 10.0 × 107 TNC/kg (13.6) | 134 (13) |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CBT, cord blood transplant; CML, chronic myelogenous leukemia; CSA, cyclosporine-A; HLA, human leukocyte antigen; JCML, juvenile chronic myelogenous leukemia; NYBC, New York Blood Center; TBI, total body irradiation; TNC, total nucleated cell; and US, United States.
Ancestry was unknown in 27 patients.
Applies to patients with ALL, AML, or CML only and was unknown in 54 patients (including 13 in remission, but the number of remissions was unknown).